About Jeffrey Tong, Ph.D.
Form D filings for Candid Therapeutics in 2024 list Jeffrey Tong, Ph.D. as director.
Jeffrey Tong, Ph.D. first appears on SEC filings in 2024.
Experience
This experience comes from SEC filings. The years are when the filings name Jeffrey Tong, Ph.D. in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Jeffrey Tong, Ph.D. works with at each company, as listed on that company's latest Form D.
Candid Therapeutics, Inc. · Form D, Sep 13, 2024
AK
Arvind Kush
Executive officer
TD
Timothy Lu, M.D.
Executive officer
KD
Kenneth Song, M.D.
President and CEO, director
AD
Aaron Royston, M.D.
Director
BD
Bernie Huyghe, Ph.D.
Executive officer
MD
Michael Rome, M.D.
Director